rs30187 — ERAP1 K528R

ERAP1 K528R — A Molecular Dimmer on the Immune Surveillance System

Every cell in your body is under constant immunological inspection. The key checkpoint is MHC class I antigen presentation¹¹ MHC class I antigen presentation
a process by which cells display short peptide fragments on their surface for surveillance by CD8+ cytotoxic T cells — abnormal peptides trigger immune attack, and the quality of that display depends critically on an upstream editing step: peptide trimming by ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)²² ERAP1 (Endoplasmic Reticulum Aminopeptidase 1)
an enzyme that clips peptides to exactly the right length (8-10 amino acids) before they can bind MHC class I molecules and reach the cell surface.

The rs30187 K528R variant changes a single amino acid in ERAP1's hinge region — and that single change fundamentally alters the enzyme's activity. The result is a miscalibrated peptide-trimming machine that shifts what your immune system sees and, in specific HLA backgrounds, increases the risk of two well-characterized autoimmune conditions: ankylosing spondylitis and psoriasis.

The Mechanism

ERAP1 acts as a molecular ruler³³ molecular ruler
the enzyme has a substrate-binding pocket that physically measures peptide length; when the peptide fits optimally, ERAP1 clips one amino acid and releases the peptide for loading onto MHC class I molecules. The enzyme cycles between an open (inactive) and closed (active) conformation. Lys528 (the common C-allele residue) sits at the hinge region that governs this conformational switch — it facilitates efficient transition to the closed, catalytically active state.

The K528R substitution (T allele) replaces lysine with arginine at position 528. Despite the chemical similarity, this change alters the kinetics of the open-to-closed transition, producing a hypofunctional enzyme⁴⁴ hypofunctional enzyme
an ERAP1 variant that trims peptides more slowly and incompletely than the common form. In biochemical assays, the K528R variant stalls at the 11-mer peptide stage — it can begin trimming but cannot efficiently complete the process to generate optimal 8-9 mer peptides. This means the T-allele ERAP1 produces a different peptide repertoire than the common enzyme: more long peptides that cannot bind MHC class I, and fewer optimal-length peptides that can.

The clinical consequence of this altered peptide landscape depends entirely on which HLA class I molecules are present in a given individual. This is why rs30187 exhibits strict epistasis⁵⁵ epistasis
a genetic interaction where the effect of one variant is entirely conditional on the genotype at a second locus with both HLA-B27 (in ankylosing spondylitis) and HLA-C*06:02 (in psoriasis).

The Evidence

Ankylosing Spondylitis: The foundational paper — a landmark GWAS meta-analysis published in Nature Genetics in 2011⁶⁶ landmark GWAS meta-analysis published in Nature Genetics in 2011
Evans et al., WTCCC2 consortium, 3,023 AS cases and 8,779 controls with replication in 2,871 cases and 9,087 controls — established that ERAP1 rs30187 is the single most functionally important coding variant in ERAP1 for AS susceptibility. The association follows strict HLA-B27 epistasis: ERAP1 variants were significantly associated with AS only in HLA-B27–positive individuals (combined P=7.3×10⁻⁶ for interaction), with no detectable association in HLA-B27–negative patients. HLA-B27–positive individuals homozygous for the protective C allele at rs30187 had approximately 3-4 times lower AS risk than HLA-B27–positive individuals carrying T-allele risk genotypes.

An updated meta-analysis incorporating 19,902 AS patients and 39,750 controls⁷⁷ updated meta-analysis incorporating 19,902 AS patients and 39,750 controls
Tian et al. 2015 confirmed the overall association (OR=1.255, 95% CI: 1.147-1.373, P=8.0×10⁻⁸), with the effect strongest in European populations (OR=1.283, 95% CI: 1.237-1.331, P<1.0×10⁻⁹).

Psoriasis: In psoriasis, rs30187 shows a more complex and bidirectional epistasis with HLA-C*06:02. A Polish cohort study⁸⁸ Polish cohort study
Szczerkowska-Dobosz et al. 2018, examining ERAP1/ERAP2 haplotypes stratified by HLA-C*06:02 status and disease onset showed that the T allele increases psoriasis risk in HLA-C*06:02 carriers (particularly late-onset disease) but is protective when HLA-C*06:02 is absent. This paradoxical direction-switching is a hallmark of epistatic interactions and underscores that the biological effect of K528R is entirely context-dependent.

A meta-analysis of nine case-control studies⁹⁹ meta-analysis of nine case-control studies
Wu et al. 2021, 4,858 psoriasis cases and 10,542 healthy controls confirmed the overall positive association (T vs C: OR=1.23, 95% CI: 1.15-1.32, P<0.00001), averaging across HLA backgrounds.

Functional validation: The mechanistic basis was confirmed by a functional study of naturally occurring ERAP1 haplotypes¹⁰¹⁰ functional study of naturally occurring ERAP1 haplotypes
Evnouchidou et al. 2013, PMC3785127 — comparative biochemical characterization of 10 ERAP1 haplotypes using diverse peptide substrates. The K528R variant consistently produced a hypofunctional enzyme across multiple substrates, generating incomplete trimming products rather than optimal 8-9 mer peptides. This directly demonstrates how the variant reshapes the peptide repertoire available for MHC class I loading.

Practical Implications

The T allele at rs30187 reduces ERAP1's peptide-editing efficiency. On its own, this is unlikely to cause disease — the altered peptide repertoire only becomes clinically meaningful when a specific HLA class I allele is present to present those aberrant or deficient peptides to the immune system.

If you carry the T allele and also carry HLA-B27 (not yet tested by GeneOps), your risk of ankylosing spondylitis is substantially elevated above the HLA-B27-only baseline. If you carry the T allele and also carry HLA-C*06:02 (check rs12191877), your risk of psoriasis is increased compared to HLA-C*06:02 carriers with the CC genotype.

Ankylosing spondylitis is a chronic inflammatory arthritis primarily affecting the spine and sacroiliac joints. It typically begins in young adulthood with morning back stiffness that improves with activity. Early diagnosis and appropriate treatment (NSAIDs, biologics targeting TNF or IL-17/IL-23) can prevent irreversible spinal fusion and maintain mobility.

Interactions

ERAP1 rs30187 × HLA-B27: Ankylosing Spondylitis Epistasis

The epistatic interaction between rs30187 and HLA-B27 in AS is one of the strongest documented gene-gene interactions in complex disease genetics. HLA-B27 presents a peptide repertoire that depends heavily on ERAP1's trimming output. The K528R variant changes which peptides are available, altering self-peptide presentation in a way that — in HLA-B27 carriers — tips the balance toward autoreactive immune activation. This interaction argues that the pathogenic mechanism of HLA-B27 in AS is fundamentally peptide-presentation-dependent.

This interaction is a candidate for compound action documentation. The relevant genotypes are: - rs30187 CT or TT (ERAP1 K528R risk allele present) combined with HLA-B27 positive status Combined recommendation: heightened AS surveillance, early rheumatological assessment for inflammatory back pain, and discussion of anti-inflammatory prophylaxis.

ERAP1 rs30187 × HLA-C*06:02 (rs12191877): Psoriasis Epistasis

The bidirectional epistasis with HLA-C*06:02 mirrors the psoriasis mechanism of the sibling variant rs27524. Where rs27524 alters ERAP1 expression levels, rs30187 alters ERAP1 catalytic efficiency — both ultimately modify the density and identity of peptides presented by HLA-C*06:02 on melanocytes. In HLA-C*06:02 carriers, the T allele's hypofunctional enzyme generates a different ADAMTSL5 peptide profile, contributing to psoriatic autoimmunity.

ERAP1 rs30187 × ERAP1 rs27524: Same-gene compound effect

rs30187 (K528R, coding missense) and rs27524 (intronic eQTL) affect ERAP1 through orthogonal mechanisms — one changes the enzyme's activity, the other changes its expression level. They co-occur on different haplotypes. The naturally occurring ERAP1 haplotype system (Hap1-Hap10) captures both variants together. Individuals inheriting risk haplotypes at both positions will have both more ERAP1 protein and less efficient ERAP1 protein — creating a complex net effect that varies by haplotype combination.